Researchers will discuss how they employed HEPATOPAC® and HEPATOMUNE® cultures in their disease modeling, lead selection, and ADME evaluation programs
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that researchers will discuss how they used its HEPATOPAC and HEPATOMUNE systems to investigate the ADME-Tox profiles of small molecule drug candidates, enable reaction phenotyping of low clearance compounds, and model fatty liver disease during its Annual HEPATOPAC User Group Meeting (HUGM). This year’s virtual event will be held online on October 28.
BioIVT’s HEPATOPAC system is an in vitro bioengineered co-culture of primary hepatocytes and fibroblasts. The system is ideal for long-term ADME studies, including metabolism and toxicity evaluation of low clearance compounds.
The company’s HEPATOMUNE system is composed of hepatocytes, stromal cells and Kupffer cells in a tri-culture, which mimics the physiological microenvironment of the liver, and provides an optimal model for studying cytokines and cytokine modulators. These cultures provide a long-term, stable, in vitro model for evaluating immune-related and inflammation-mediated liver injury.
“We are delighted to be able to continue to share research advances conducted using the HEPATOPAC and HEPATOMUNE systems. With the ongoing challenges caused by the COVID pandemic, it is more important than ever now to provide venues like the HUGM where researchers can explore new research ideas and areas for collaboration even when working remotely. This year’s case studies will demonstrate how these long-term hepatocyte systems provide a unique platform for modeling pharmacokinetics of investigational new drugs,” said Chris Black, PhD, BioIVT Senior Vice President ADME-Tox.
During this year’s HUGM, T. Eric Ballard, PhD, Associate Scientific Director at Takeda, will describe “Applications of a Micropatterned Co-cultured (MPCC) Hepatocyte System to Support Small Molecule Drug Discovery and Development.”
He will be followed by Sheri Smith, Senior Research Scientist at Merck, who will address “Reaction Phenotyping of Low-Turnover Compounds in HEPATOPAC Systems Through Persistent Selective Inhibition of Cytochromes P450.”
Then, Stephen Fowler, PhD, Clinical Pharmacologist at Roche, will present “Validation of the Human HEPATOPAC System for Clearance Prediction of UGT Metabolized Drugs.”
Lastly, Karissa Cottier, PhD, Principal Scientist at BioIVT, will discuss “Modeling Fatty Liver Disease Using the HEPATOPAC and HEPATOMUNE Culture Systems: Methods and Applications.”
Additional information about this complimentary event is available at https://info.bioivt.com/hugm-2021-reg?utm_referrer=https%3A%2F%2Fbioivt.com%2F.